85.7 F
San Fernando
Monday, Apr 22, 2024

MannKind Closes Sanofi Deal

MannKind Corp. announced on Wednesday that it has closed its worldwide marketing deal with French drug maker Sanofi for its Afreeza inhalable insulin. The Valencia biotech said as part of the deal it will receive a $150 million upfront payment from the Paris-based company in the next 10 days. Under the licensing agreement, MannKind will manufacture Afrezza at its plant in Danbury, Conn., while Sanofi will take responsibility for marketing and regulatory compliance. MannKind will receive 35 percent of all profits, while Sanofi will retain 65 percent. The closing follows completion of paperwork for a $175 million credit line provided to MannKind by a Sanofi affiliate to pay for manufacturing expenses. Afrezza was approved for sale by the Food and Drug Administration in July. Shares of MannKind closed up 6 cents, or 1 percent, to $6.08 on the Nasdaq.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.

Featured Articles

Related Articles